BioSpace News Archive

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of updated clinical data from its ongoing trial evaluating ALX148 in combination with rituximab for the treatment of patients with advanced relapsed and refractory (“r/r”) non-Hodgkin lymphoma (“NHL”).

62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or BTK mutation status Similar overall response rates observed in patients previously treated with all classes of available therapy (chemotherapy, anti-CD20 antibodies, BTK inhibitors, BCL2 inhibitors, PI3K-delta inhibitors) 94% of responding patients remain in response and on ther

Further analyses from the Phase 3 ANDROMEDA study at ASH 2020 highlight potential of DARZALEX FASPRO® in treatment of rare blood disease

Treatment options did not provide hematocrit control consistent with NCCN guidelines for up to 78 percent of patients as presented at the American Society for Hematology (ASH) 2020 annual meeting

- PRGN-3006 has been safe and well-tolerated to date - - Case study demonstrated persistence of PRGN-3006 administered without prior lymphodepletion in blood at seven months post-infusion and reduction in blood and bone marrow blasts - - Milestone marks a global first report of direct infusion of non-expanded CAR-T cells leading to in vivo expansion and long-term persistence in patients -

Seagen Announces Multiple ADCETRIS ® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting - Five-Year Update of the ECHELON-1 Clinical Trial Shows Treatment with ADCETRIS in Combination with AVD Chemotherapy Results in Superior Long-Term Outcomes when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma -

Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announce that preliminary data from firstMIND, the ongoing Phase 1b, open-label, randomized study on the safety and efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria, during the American Institute of Ch

Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay and now allows the use of saliva as an approved sample type. The fully automated sample-to-answer assay was initially authorized for use on a range of respiratory specimens under EUA on April 29, 2020. The ability to test saliva samples for

OPEN MINDS has announced that The Non-Profit Mergers, Acquisitions, & Affiliations Summit: Collaborations For Sustainability In The Next Normal will be held on March 9, 2021 prior to the annual OPEN MINDS Technology & Analytics Institute which will be held on March 10 and 11, 2021.